4-AcO-DMT

Closure of psx:substance/4-aco-dmt/section/pharmacology.full@1: 44 upstream, 42 downstream.

psx:substance/4-aco-dmt/section/pharmacology.full@1
├─ informed_by  claim/550e91ac-8658-40b3-8428-aebc20c8ca9f  Claim in pharmacology — inconclusive  working
├─ informed_by  claim/b0bbf754-f76b-41d1-a54b-f650a6ea8b75  Claim in pharmacology — inconclusive  working
├─ informed_by  claim/3f7cc258-d1ec-4e95-bfac-0ed5ce1783b8  Claim in pharmacology — supported
├─ informed_by  claim/a1931c29-e085-43a0-854c-a643629bdd04  Claim in pharmacology — supported
├─ informed_by  claim/d9ce289b-3fac-409f-b14d-b718b6080e3f  Claim in pharmacology — supported
├─ informed_by  claim/58756367-b293-4f71-86aa-4baef8afad2b  Claim in pharmacology — inconclusive  working
├─ informed_by  claim/b9b428a9-a36b-42e2-a06a-a4558a4e9a57  Claim in pharmacology — inconclusive  working
├─ informed_by  claim/e9058156-ed38-4fb6-bded-a0ff45169554  Claim in pharmacology — inconclusive  working
├─ informed_by  claim/dd88e857-8427-4211-b938-c7f622a31ec7  Claim in pharmacology — supported
├─ informed_by  claim/a4e5c24d-9833-4626-9fc2-17480de00a81  Claim in pharmacology — supported
├─ informed_by  claim/017d8a68-0053-48fc-939e-7c5a7b596853  Claim in pharmacology — supported
├─ informed_by  claim/c5d57f99-a493-47d5-ac6e-6aa4c6722b0c  Claim in pharmacology — not_supported  working
├─ informed_by  claim/a7fa3081-eb05-414f-96a6-66aaf72be87a  Claim in pharmacology — supported
├─ informed_by  claim/9b8f8caa-bf61-4028-9717-3c28894e6602  Claim in pharmacology — inconclusive  working
├─ informed_by  claim/2b9b3a2b-b8a1-4f10-ab03-76ae6b6203c5  Claim in pharmacology — inconclusive  working
├─ informed_by  claim/6d01ed86-77db-41e0-8784-2ec91c09e019  Claim in pharmacology — supported
  ├─ used  src/doi:10.1007/7854_2017_475  Chemistry and Structure-Activity Relationships of Psychedelics.
  ├─ used  src/doi:10.1016/j.cell.2020.08.024  Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
  ├─ used  src/doi:10.1002/dta.3255  Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS
  ├─ used  src/doi:10.3389/fpsyt.2023.1303365  In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin
  ├─ used  src/doi:10.1021/acsptsci.2c00177  Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice
  ├─ used  src/doi:10.1016/j.neuron.2025.06.012  The polypharmacology of psychedelics reveals multiple targets for potential therapeutics
  ├─ used  src/doi:10.1021/acsptsci.2c00222  Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice
  ├─ used  src/doi:10.1007/s00204-024-03952-7  Elucidating the Phase I metabolism of psilocin in vitro
  ├─ used  src/doi:10.3390/pharmaceutics17040411  Pharmacokinetics of Psilocybin: A Systematic Review
  ├─ used  src/doi:10.1007/s40262-024-01454-4  Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis
      ├─ used  src/doi:10.1055/s-1999-3490  Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin
      ├─ used  src/doi:10.1016/j.neulet.2023.137597  Rewarding Effects of the Hallucinogen 4-AcO-DMT Administration and Withdrawal in Rats: A Challenge to the Opponent-Process Theory
      ├─ used  src/doi:10.1007/s00204-026-04365-4  In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin
      ├─ used  src/url:7a90964f24ed4f5d  4-AcO-DMT (Psilacetin) - Erowid Basics
      ├─ used  src/url:946c31199207c835  4-AcO-DMT
      ├─ used  src/doi:10.1107/s2056989019007370  Bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate: a new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrug
      ├─ used  src/doi:10.1111/1556-4029.15167  Psilocin - The 'real deal' or an extraction byproduct
      ├─ used  src/doi:10.1111/bph.70307  5-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuation
      ├─ used  src/doi:10.1016/j.euroneuro.2016.05.001  Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
      ├─ used  src/doi:10.3390/life13122345  Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue
      ├─ used  src/doi:10.3390/cimb45080427  Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells
      ├─ used  src/doi:10.1007/s00204-020-02693-7  Designer drugs: mechanism of action and adverse effects
      ├─ used  src/doi:10.3390/brainsci8030047  Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives
      ├─ used  src/doi:10.3389/fphar.2017.00423  A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects
      ├─ used  src/doi:10.1016/j.celrep.2023.112203  A non-hallucinogenic LSD analog with therapeutic potential for mood disorders
      ├─ used  src/pmid:16051647  Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.
      ├─ used  src/doi:10.1007/s40263-025-01256-7  Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances
      └─ generated_by  pub/9aa9e7e9-e7aa-40c4-b484-d5fa3248e35f  Publication — backfill
    ├─ used  version/1  Revision 1
    ├─ used  claim/ff3f3dfc-0129-4863-8282-c15d5e46c69c  Claim in safety — inconclusive  working
    ├─ used  claim/f894156e-b5ac-4d13-958d-46d48eceeb4c  Claim in chemistry — inconclusive  working
    ├─ used  claim/c05aa42c-ac1e-4997-b1c7-9b09da78980b  Claim in summary — supported
    ├─ used  claim/65e8ce5d-f204-4d39-9ee6-dfe1d10ad7af  Claim in history — supported
    ├─ used  claim/31b050c2-db3b-4d9e-9c99-16e12954691d  Claim in chemistry — supported
    ├─ used  claim/c7280ee1-74df-4692-94e2-ff56b7365a69  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/26c749eb-394a-424f-ac3a-2f768edceea6  Claim in history — supported
    ├─ used  claim/abc4973f-18e2-49d4-b628-b4946444a58a  Claim in chemistry — supported
    ├─ used  claim/fcd3b5f9-5cdb-4a5d-9f7c-aef907ee80a5  Claim in pharmacokinetic-detail — supported
    ├─ used  claim/df9f36ff-5a48-4bbc-bd16-7b84d9d7c9f3  Claim in comparative-pharmacology — supported
    ├─ used  claim/3617354c-493e-4341-bb74-24bc8d3dd21c  Claim in summary — supported
    ├─ used  claim/e478bf38-094d-4fad-bc17-ac5ed8ed3a55  Claim in chemistry — inconclusive  working
    ├─ used  claim/52d0ee3d-6868-4a61-9c92-ebd19e022f15  Claim in chemistry — inconclusive  working
    ├─ used  claim/0fb0121c-5009-416c-9c8c-c7a5ee68b425  Claim in clinical-evidence — supported
    ├─ used  claim/b25d9ff3-863f-4ab3-a3e4-afa024fcf0ae  Claim in comparative-pharmacology — supported
    ├─ used  claim/eaae7ee1-b8f0-44ed-851d-c556678e655c  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/7bd8cdaa-b105-4214-a097-86bb7cf574bb  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/54a78cdf-4e10-4f50-9d10-303ac85afe4f  Claim in summary — inconclusive  working
    ├─ used  claim/0985b16c-2ceb-4d03-b969-e974fcc2b3ab  Claim in history — inconclusive  working
    ├─ used  claim/e86c8e89-6a23-4a84-8474-5b5a5e30ad1c  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/8eb7ef5e-d5fa-4a3d-9f62-dd19c24812de  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/c817495f-7b81-4865-8bb7-ea1603549af6  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/44d7bb43-e7a6-487e-9798-522b526059c4  Claim in safety — supported
    ├─ used  claim/a5ee8056-ef18-4f6d-b46f-8838920c895f  Claim in safety — not_supported  working
    ├─ used  claim/3010606d-ab9b-461d-9cd2-d42aae4d1132  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/8055509d-035d-4276-b4e2-578bc79a37c5  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/637b29ab-3b0b-455f-b45e-6595e483c936  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ derived_from  issue/notice@b90cab31cadf  Issued notice
      ├─ derived_from  issue/info_card@2b6c0a7b280e  Issued info_card
      ├─ derived_from  issue/emergency@3f0909c25c71  Issued emergency
      ├─ derived_from  issue/notice@9a96b1160ba9  Issued notice
      ├─ derived_from  issue/info_card@017f70fc6826  Issued info_card
      ├─ derived_from  issue/emergency@c15c760aabf6  Issued emergency
      ├─ informed_by  section/safety.full@1
      ├─ informed_by  section/chemistry.full@1
      ├─ informed_by  section/summary.full@1
      ├─ informed_by  section/history.full@1
      ├─ informed_by  section/pharmacokinetic-detail.full@1
      ├─ informed_by  section/comparative-pharmacology.full@1
      ├─ informed_by  section/clinical-evidence.full@1
      └─ informed_by  section/receptor-pharmacology.full@1
… closure truncated at 200 nodes

indented by distance from this node, not by parentage